乳癌液態切片市場規模、佔有率、成長分析（按循環生物標記、應用、地區）- 產業預測，2024-2031 年

2022年全球液態切片市場規模為10.1億美元，從2023年的12.4億美元成長到2031年的63.7億美元，預計在預測期間（2024-2031年）將以複合年成長率成長。 %。

在人們對非侵入性診斷方法的認知和採用不斷提高的推動下，全球液態切片市場正在顯著成長。這項創新技術有助於檢測腫瘤特異性基因突變、循環性腫瘤細胞和遊離 DNA，這對於早期診斷、治療方法選擇和監測治療反應至關重要。隨著正在進行的研究和開發提高液態切片測試的靈敏度和特異性，預計市場將會擴大。生物技術公司和醫療機構之間的合作，加上對個人化和針對性乳癌治療的需求不斷成長，正在進一步推動市場擴張。總體而言，技術創新和臨床應用的結合可能會推動液態切片市場在未來幾年顯著成長。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 案例研究分析

液態切片市場規模：按循環生物標記和複合年成長率（2024-2031）

• 市場概況
• 循環性腫瘤細胞（CTCS）
• 循環遊離 DNA (CFDNA)
• 細胞外囊泡（EVS）
• 其他循環生物標記

液態切片市場規模：按應用和複合年成長率（2024-2031）

• 市場概況
• 早期發現/篩檢
• 診斷
• 治療選擇
• 監視

液態切片市場規模：按最終用戶和複合年成長率（2024-2031）

• 市場概況
• 醫院
• 診所
• 其他

液態切片市場規模及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Guardant Health Inc.
• QIAGEN
• Biocept Inc.
• Thermo Fisher Scientific
• Adaptive Biotechnologies
• Myriad Genetics
• Fluxion Biosciences Inc.
• Biodesix
• Exosome Diagnostics Inc.
• Epic Sciences
• PapGene
• Pathway Genomics（OME Care）
• Agena Bioscience
• MDxHealth
• Janssen Diagnostics
• Abbott

結論和建議

Global Breast Cancer Liquid Biopsy Market size was valued at USD 1.01 billion in 2022 and is poised to grow from USD 1.24 billion in 2023 to USD 6.37 billion by 2031, growing at a CAGR of 22.7% during the forecast period (2024-2031).

The global breast cancer liquid biopsy market is witnessing substantial growth, spurred by rising awareness and the adoption of non-invasive diagnostic methods. This innovative technology facilitates the detection of tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA, critical for early diagnosis, treatment selection, and monitoring responses to therapies. As ongoing research and development improve the sensitivity and specificity of liquid biopsy tests, market expansion is anticipated. Collaborative efforts between biotech firms and healthcare institutions, coupled with increasing demand for personalized and targeted breast cancer therapies, are further propelling the market's progression. Overall, the convergence of innovation and clinical application positions the liquid biopsy market for notable growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breast Cancer Liquid Biopsy Market Segmental Analysis

Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Breast Cancer Liquid Biopsy Market

The global breast cancer liquid biopsy market is primarily propelled by the growing demand to effectively tackle breast cancer. The rising use of liquid biopsy methods serves as a key motivator, as these techniques facilitate the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and various biomarkers found in blood samples. This innovation enables healthcare providers to make better-informed treatment choices. Furthermore, liquid biopsies can detect resistance mutations and minimal residual disease, enhancing personalized treatment approaches. As a result, this technology not only improves patient outcomes but also contributes to lowering overall healthcare expenses.

Restraints in the Global Breast Cancer Liquid Biopsy Market

The global breast cancer liquid biopsy market faces several significant restraints, primarily stemming from inadequate investment in healthcare infrastructure. While liquid biopsy tests show considerable promise, their high costs present a substantial barrier to accessibility, particularly for patients with limited financial means or those in areas with poor healthcare funding. The considerable investment required for the development and deployment of advanced liquid biopsy technologies often leads to elevated testing costs, making them less feasible for many individuals. Furthermore, challenges related to reimbursement policies and regulatory approvals hamper widespread adoption, highlighting the critical need to address these financial barriers to enhance equitable access to these crucial diagnostic tools for breast cancer patients worldwide.

Market Trends of the Global Breast Cancer Liquid Biopsy Market

The Global Breast Cancer Liquid Biopsy market is witnessing a significant upward trend, driven by the increasing demand for non-invasive diagnostic methods aimed at early detection and monitoring of breast cancer. As healthcare professionals and patients alike seek alternatives to traditional tissue biopsies, liquid biopsies are gaining traction for their ability to provide timely and accurate genomic insights with minimal discomfort. Technological advancements in assay development and an escalating focus on personalized medicine are further propelling this market. Additionally, rising awareness and supportive regulatory frameworks are fostering a conducive environment for innovation, ultimately driving growth in the breast cancer liquid biopsy sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Study Analysis

Global Breast Cancer Liquid Biopsy Market Size by Circulating Biomarkers & CAGR (2024-2031)

• Market Overview
• Circulating Tumor Cells (CTCS)
• Circulating Cell-Free DNA (CFDNA)
• Extracellular Vesicles (EVS)
• Other Circulating Biomarkers

Global Breast Cancer Liquid Biopsy Market Size by Application & CAGR (2024-2031)

• Market Overview
• Early Detection/Screening
• Diagnosis
• Treatment Selection
• Monitoring

Global Breast Cancer Liquid Biopsy Market Size by End Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Others

Global Breast Cancer Liquid Biopsy Market Size & CAGR (2024-2031)

• North America (Circulating Biomarkers, Application, End Users)
  • USA
  • Canada
• Europe (Circulating Biomarkers, Application, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Circulating Biomarkers, Application, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Circulating Biomarkers, Application, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Circulating Biomarkers, Application, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocept Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluxion Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biodesix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exosome Diagnostics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epic Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PapGene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pathway Genomics (OME Care)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agena Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MDxHealth
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations